Elisa Latorre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elisa Latorre has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Provenzani
University of Trento
9 shared publications - Chiara Zucal
Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy
4 shared publications - Anna Maria Di Giulio
Laboratory of Pharmacology, Department of Health Sciences, University of Milan, Via A. di Rudinì 8, 20142 Milan, Italy
3 shared publications Ilaria Castiglioni
Laboratory of Genomic Screening, Center for Integrative Biology, University of Trento, Trento, Italy
3 shared publications- Natthakan Thongon
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3 shared publications - Stephana Carelli
Center of Newborn Screening, Functional Genomics and Rare Diseases, Department of Pediatrics, Buzzi Children’s Hospital, 20154 Milan, Italy
3 shared publications
Latest Publications
- Open Access
- 26 July 2019
- Published by Taylor & Francis in RNA Biology
- Vol. 16 (10) , 1471-1485
HuR interacts with lincBRN1a and lincBRN1b during neuronal stem cells differentiation
LncRNAs play crucial roles in cellular processes and their regulatory effects in the adult brain and neural stem cells (NSCs) remain to be entirely characterized. We report that 10 lncRNAs (LincENC1, FABL, lincp21, HAUNT, PERIL, lincBRN1a, lincBRN1b, HOTTIP, TUG1 and FENDRR) are expressed during murine NSCs differentiation and interact with the RNA-binding protein ELAVL1/HuR. Furthermore, we characterize the function of two of the deregulated lncRNAs, lincBRN1a and lincBRN1b, during NSCs’ differentiation. Their inhibition leads to the induction of differentiation, with a concomitant decrease in stemness and an increase in neuronal markers, indicating that they exert key functions in neuronal cells differentiation. Furthermore, we describe here that HuR regulates their half-life, suggesting their synergic role in the differentiation process. We also identify six human homologs (PANTR1, TUG1, HOTTIP, TP53COR, ELDRR and FENDRR) of the mentioned 10 lncRNAs and we report their deregulation during human iPSCs differentiation into neurons. In conclusion, our results strongly indicate a key synergic role for lncRNAs and HuR in neuronal stem cells fate.
- 26 July 2019
- Published by Taylor & Francis in RNA Biology
- Vol. 16 (10) , 1471-1485
Open AccessHuR interacts with lincBRN1a and lincBRN1b during neuronal stem cells differentiation
LncRNAs play crucial roles in cellular processes and their regulatory effects in the adult brain and neural stem cells (NSCs) remain to be entirely characterized. We report that 10 lncRNAs (LincENC1, FABL, lincp21, HAUNT, PERIL, lincBRN1a, lincBRN1b, HOTTIP, TUG1 and FENDRR) are expressed during murine NSCs differentiation and interact with the RNA-binding protein ELAVL1/HuR. Furthermore, we characterize the function of two of the deregulated lncRNAs, lincBRN1a and lincBRN1b, during NSCs’ differentiation. Their inhibition leads to the induction of differentiation, with a concomitant decrease in stemness and an increase in neuronal markers, indicating that they exert key functions in neuronal cells differentiation. Furthermore, we describe here that HuR regulates their half-life, suggesting their synergic role in the differentiation process. We also identify six human homologs (PANTR1, TUG1, HOTTIP, TP53COR, ELDRR and FENDRR) of the mentioned 10 lncRNAs and we report their deregulation during human iPSCs differentiation into neurons. In conclusion, our results strongly indicate a key synergic role for lncRNAs and HuR in neuronal stem cells fate.
- 1 June 2017
- Published by Elsevier in Neuropharmacology
- Vol. 119, 76-90
Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors
- 1 June 2017
- Published by Elsevier in Neuropharmacology
- Vol. 119, 76-90
Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors
- 1 May 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (9) , 2626-2636
The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial–Mesenchymal Transition in Breast Cancer
Epithelial-to-mesenchymal transition (EMT) is a core process underlying cell movement during embryonic development and morphogenesis. Cancer cells hijack this developmental program to execute a multi-step cascade, leading to tumorigenesis and metastasis. CD133 (PROM1), a marker of cancer stem cells, has been shown to facilitate EMT in various cancers, but the regulatory networks controlling CD133 gene expression and function in cancer remain incompletely delineated. In this study, we show that a ribonucleoprotein complex including the long noncoding RNA MALAT1 and the RNA-binding protein HuR (ELAVL1) binds the CD133 promoter region to regulate its expression. In luminal nonmetastatic MCF-7 breast cancer cells, HuR silencing was sufficient to upregulate N-cadherin (CDH2) and CD133 along with a migratory and mesenchymal-like phenotype. Furthermore, we found that in the basal-like metastatic cell line MDA-MB-231 and primary triple-negative breast cancer tumor cells, the repressor complex was absent from the CD133-regulatory region, but was present in the MCF-7 and primary ER+ tumor cells. The absence of the complex from basal-like cells was attributed to diminished expression of MALAT1, which, when overexpressed, dampened CD133 levels. In conclusion, our findings suggest that the failure of a repressive complex to form or stabilize in breast cancer promotes CD133 upregulation and an EMT-like program, providing new mechanistic insights underlying the control of prometastatic processes. Cancer Res; 76(9); 1–11. ©2016 AACR.
- 1 May 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (9) , 2626-2636
The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial–Mesenchymal Transition in Breast Cancer
Epithelial-to-mesenchymal transition (EMT) is a core process underlying cell movement during embryonic development and morphogenesis. Cancer cells hijack this developmental program to execute a multi-step cascade, leading to tumorigenesis and metastasis. CD133 (PROM1), a marker of cancer stem cells, has been shown to facilitate EMT in various cancers, but the regulatory networks controlling CD133 gene expression and function in cancer remain incompletely delineated. In this study, we show that a ribonucleoprotein complex including the long noncoding RNA MALAT1 and the RNA-binding protein HuR (ELAVL1) binds the CD133 promoter region to regulate its expression. In luminal nonmetastatic MCF-7 breast cancer cells, HuR silencing was sufficient to upregulate N-cadherin (CDH2) and CD133 along with a migratory and mesenchymal-like phenotype. Furthermore, we found that in the basal-like metastatic cell line MDA-MB-231 and primary triple-negative breast cancer tumor cells, the repressor complex was absent from the CD133-regulatory region, but was present in the MCF-7 and primary ER+ tumor cells. The absence of the complex from basal-like cells was attributed to diminished expression of MALAT1, which, when overexpressed, dampened CD133 levels. In conclusion, our findings suggest that the failure of a repressive complex to form or stabilize in breast cancer promotes CD133 upregulation and an EMT-like program, providing new mechanistic insights underlying the control of prometastatic processes. Cancer Res; 76(9); 1–11. ©2016 AACR.
- Open Access
- 28 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (18) , 26551-26566
The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Natthakan Thongon1, *, Ilaria Castiglioni2, *, Chiara Zucal1, Elisa Latorre1, Vito D’Agostino1, Inga Bauer3, Michael Pancher4, Alberto Ballestrero3, Georg Feldmann5, Alessio Nencioni3, Alessandro Provenzani1 1Laboratory of Genomic Screening, Centre for Integrative Biology, University of Trento, Trento, Italy 2Laboratory of Gene Expression and Muscular Dystrophy, San Raffaele Scientific Institute, Milan, Italy 3Department of Internal Medicine, University of Genoa, Genoa, Italy 4High Throughput Screening Facility, Centre for Integrative Biology, University of Trento, Trento, Italy 5Laboratory of Pancreatic Cancer Translational Research, Clinic University of Bonn, Bonn, Germany *These authors have contributed equally to this work Correspondence to: Alessandro Provenzani, email: alessandro.provenzani@unitn.it Keywords: YAP, EMT, CTGF, PDAC, bisindolylmaleimides Received: August 28, 2015 Accepted: March 06, 2016 Published: March 28, 2016 ABSTRACT The Yes-associated protein, YAP, is a transcriptional co-activator, mediating the Epithelial to Mesenchymal Transition program in pancreatic ductal adenocarcinoma (PDAC). With the aim to identify compounds that can specifically modulate YAP functionality in PDAC cell lines, we performed a small scale, drug-based screening experiment using YAP cell localization as the read-out. We identified erlotinib as an inducer of YAP cytoplasmic localization, an inhibitor of the TEA luciferase reporter system and the expression of the bona fide YAP target gene, Connective Tissue Growth Factor CTGF. On the other hand, BIS I, an inhibitor of PKCδ and GSK3β, caused YAP accumulation into the nucleus. Activation of β-catenin reporter and interfering experiments show that inhibition of the PKCδ/GSK3β pathway triggers YAP nuclear accumulation inducing YAP/TEAD transcriptional response. Inhibition of GSK3β by BIS I reduced the expression levels of SMADs protein and reduced YAP contribution to EMT. Notably, BIS I reduced proliferation, migration and clonogenicity of PDAC cells in vitro, phenocopying YAP genetic down-regulation. As shown by chromatin immunoprecipitation experiments and YAP over-expressing rescue experiments, BIS I reverted YAP-dependent EMT program by modulating the expression of the YAP target genes E-cadherin, vimentin, CTGF and of the newly identified target, CD133. In conclusion, we identified two different molecules, erlotinib and BIS I, modulating YAP functionality although via different mechanisms of action, with the second one specifically inhibiting the YAP-dependent EMT program in PDAC cell lines.
- 28 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (18) , 26551-26566
Open AccessThe GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Natthakan Thongon1, *, Ilaria Castiglioni2, *, Chiara Zucal1, Elisa Latorre1, Vito D’Agostino1, Inga Bauer3, Michael Pancher4, Alberto Ballestrero3, Georg Feldmann5, Alessio Nencioni3, Alessandro Provenzani1 1Laboratory of Genomic Screening, Centre for Integrative Biology, University of Trento, Trento, Italy 2Laboratory of Gene Expression and Muscular Dystrophy, San Raffaele Scientific Institute, Milan, Italy 3Department of Internal Medicine, University of Genoa, Genoa, Italy 4High Throughput Screening Facility, Centre for Integrative Biology, University of Trento, Trento, Italy 5Laboratory of Pancreatic Cancer Translational Research, Clinic University of Bonn, Bonn, Germany *These authors have contributed equally to this work Correspondence to: Alessandro Provenzani, email: alessandro.provenzani@unitn.it Keywords: YAP, EMT, CTGF, PDAC, bisindolylmaleimides Received: August 28, 2015 Accepted: March 06, 2016 Published: March 28, 2016 ABSTRACT The Yes-associated protein, YAP, is a transcriptional co-activator, mediating the Epithelial to Mesenchymal Transition program in pancreatic ductal adenocarcinoma (PDAC). With the aim to identify compounds that can specifically modulate YAP functionality in PDAC cell lines, we performed a small scale, drug-based screening experiment using YAP cell localization as the read-out. We identified erlotinib as an inducer of YAP cytoplasmic localization, an inhibitor of the TEA luciferase reporter system and the expression of the bona fide YAP target gene, Connective Tissue Growth Factor CTGF. On the other hand, BIS I, an inhibitor of PKCδ and GSK3β, caused YAP accumulation into the nucleus. Activation of β-catenin reporter and interfering experiments show that inhibition of the PKCδ/GSK3β pathway triggers YAP nuclear accumulation inducing YAP/TEAD transcriptional response. Inhibition of GSK3β by BIS I reduced the expression levels of SMADs protein and reduced YAP contribution to EMT. Notably, BIS I reduced proliferation, migration and clonogenicity of PDAC cells in vitro, phenocopying YAP genetic down-regulation. As shown by chromatin immunoprecipitation experiments and YAP over-expressing rescue experiments, BIS I reverted YAP-dependent EMT program by modulating the expression of the YAP target genes E-cadherin, vimentin, CTGF and of the newly identified target, CD133. In conclusion, we identified two different molecules, erlotinib and BIS I, modulating YAP functionality although via different mechanisms of action, with the second one specifically inhibiting the YAP-dependent EMT program in PDAC cell lines.
- Open Access
- 1 February 2016
- Published by Elsevier in Molecular Pharmacology
- Vol. 89 (2) , 243-252
Human Antigen R Binding and Regulation of SOX2 mRNA in Human Mesenchymal Stem Cells
Since 2005, SOX2 has raised the attention of the scientific community for being one of the key transcription factors responsible for pluripotency induction in somatic stem cells. Our research investigated the turnover regulation of SOX2 mRNA in human adipose-derived stem cells, considered one of the most valuable sources of somatic stem cells in regenerative medicine. Mitoxantrone, is a drug acting on nucleic acids primarily used to treat certain types of cancer, and recently re-addressed to ameliorate the outcome of autoimmune diseases such as multiple sclerosis. Additionally, mitoxantrone has been shown to inhibit the binding of Human antigen R (HuR) RNA binding protein to TNF alpha mRNA. Our results show that HuR binds to the 3'UTR region of SOX2 mRNA together with the RNA-induced silencing complex-miR145. The HuR binding works by stabilizing the interaction between the 3' UTR and RISC. Cell exposure to mitoxantrone leads to HuR detachment, and the subsequent prolongation of the SOX2 mRNA half-life. The prolonged SOX2 half-life allows to an improvement of the spheroid forming capability of the adipose-derived stem cells. The silencing of HuR confirmed the above observations, and illustrates how the RNA binding protein HuR may be a required molecule for regulation of SOX2 mRNA decay.
- 1 February 2016
- Published by Elsevier in Molecular Pharmacology
- Vol. 89 (2) , 243-252
Open AccessHuman Antigen R Binding and Regulation of SOX2 mRNA in Human Mesenchymal Stem Cells
Since 2005, SOX2 has raised the attention of the scientific community for being one of the key transcription factors responsible for pluripotency induction in somatic stem cells. Our research investigated the turnover regulation of SOX2 mRNA in human adipose-derived stem cells, considered one of the most valuable sources of somatic stem cells in regenerative medicine. Mitoxantrone, is a drug acting on nucleic acids primarily used to treat certain types of cancer, and recently re-addressed to ameliorate the outcome of autoimmune diseases such as multiple sclerosis. Additionally, mitoxantrone has been shown to inhibit the binding of Human antigen R (HuR) RNA binding protein to TNF alpha mRNA. Our results show that HuR binds to the 3'UTR region of SOX2 mRNA together with the RNA-induced silencing complex-miR145. The HuR binding works by stabilizing the interaction between the 3' UTR and RISC. Cell exposure to mitoxantrone leads to HuR detachment, and the subsequent prolongation of the SOX2 mRNA half-life. The prolonged SOX2 half-life allows to an improvement of the spheroid forming capability of the adipose-derived stem cells. The silencing of HuR confirmed the above observations, and illustrates how the RNA binding protein HuR may be a required molecule for regulation of SOX2 mRNA decay.
- Open Access
- 10 November 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 16478
Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function
Post-transcriptional regulation is an essential determinant of gene expression programs in physiological and pathological conditions. HuR is a RNA-binding protein that orchestrates the stabilization and translation of mRNAs, critical in inflammation and tumor progression, including tumor necrosis factor-alpha (TNF). We identified the low molecular weight compound 15,16-dihydrotanshinone-I (DHTS), well known in traditional Chinese medicine practice, through a validated high throughput screening on a set of anti-inflammatory agents for its ability to prevent HuR:RNA complex formation. We found that DHTS interferes with the association step between HuR and the RNA with an equilibrium dissociation constant in the nanomolar rangein vitro(Ki = 3.74 ± 1.63 nM). In breast cancer cell lines, short term exposure to DHTS influences mRNA stability and translational efficiency of TNF in a HuR-dependent manner and also other functional readouts of its post-transcriptional control, such as the stability of selected pre-mRNAs. Importantly, we show that migration and sensitivity of breast cancer cells to DHTS are modulated by HuR expression, indicating that HuR is among the preferential intracellular targets of DHTS. Here, we disclose a previously unrecognized molecular mechanism exerted by DHTS, opening new perspectives to therapeutically target the HuR mediated, post-transcriptional control in inflammation and cancer cells.
- 10 November 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 16478
Open AccessDihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function
Post-transcriptional regulation is an essential determinant of gene expression programs in physiological and pathological conditions. HuR is a RNA-binding protein that orchestrates the stabilization and translation of mRNAs, critical in inflammation and tumor progression, including tumor necrosis factor-alpha (TNF). We identified the low molecular weight compound 15,16-dihydrotanshinone-I (DHTS), well known in traditional Chinese medicine practice, through a validated high throughput screening on a set of anti-inflammatory agents for its ability to prevent HuR:RNA complex formation. We found that DHTS interferes with the association step between HuR and the RNA with an equilibrium dissociation constant in the nanomolar rangein vitro(Ki = 3.74 ± 1.63 nM). In breast cancer cell lines, short term exposure to DHTS influences mRNA stability and translational efficiency of TNF in a HuR-dependent manner and also other functional readouts of its post-transcriptional control, such as the stability of selected pre-mRNAs. Importantly, we show that migration and sensitivity of breast cancer cells to DHTS are modulated by HuR expression, indicating that HuR is among the preferential intracellular targets of DHTS. Here, we disclose a previously unrecognized molecular mechanism exerted by DHTS, opening new perspectives to therapeutically target the HuR mediated, post-transcriptional control in inflammation and cancer cells.
- Open Access
- 17 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (37) , 39980-39994
The 5′-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding
The 5′-untranslated region of p16 INK4 a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding
- 17 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (37) , 39980-39994
Open AccessThe 5′-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding
The 5′-untranslated region of p16 INK4 a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding
- 4 May 2015
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 16 (5) , 499-515
Targeting the Multifaceted HuR Protein, Benefits and Caveats
The RNA-binding protein (RBP) HuR is one of the most widely studied regulators of the eukaryotic posttranscriptional gene expression and it plays a physiological role in mediating the cellular response to apoptotic, proliferating and survival stimuli. Following physiological or stress stimuli, HuR protein binds to Adenylate-Urydinilate rich elements (AREs) generally contained in the 3’UTR of transcripts, then it shuttles from the nucleus to the cytoplasm and regulates the half-life and/or translation of cargo mRNAs. Derangements in sub-cellular localization and expression of HuR have been associated with the pathophysiology of many diseases and this protein has been proposed as a potential drug target. Recent findings also re-evaluated HuR as a splicing and polyadenylation factor, expanding its spectrum of functional activity up to the maturation of pre-mRNAs. In this review, we generate a comprehensive picture of HuR functionality to discuss the implications of considering HuR as pharmacological target and the detrimental or positive impact that can be expected upon its modulation. Firstly, we focus on the recent findings about the mechanistic role of HuR in the nucleus and in the regulation of long non coding RNAs; then we describe the animal models and the clinical association and significance in cancer; finally, we have reviewed the pharmacological tools that influence HuR’s post-transcriptional control and the efforts made to identify specific HuR inhibitors.
- 4 May 2015
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 16 (5) , 499-515
Targeting the Multifaceted HuR Protein, Benefits and Caveats
The RNA-binding protein (RBP) HuR is one of the most widely studied regulators of the eukaryotic posttranscriptional gene expression and it plays a physiological role in mediating the cellular response to apoptotic, proliferating and survival stimuli. Following physiological or stress stimuli, HuR protein binds to Adenylate-Urydinilate rich elements (AREs) generally contained in the 3’UTR of transcripts, then it shuttles from the nucleus to the cytoplasm and regulates the half-life and/or translation of cargo mRNAs. Derangements in sub-cellular localization and expression of HuR have been associated with the pathophysiology of many diseases and this protein has been proposed as a potential drug target. Recent findings also re-evaluated HuR as a splicing and polyadenylation factor, expanding its spectrum of functional activity up to the maturation of pre-mRNAs. In this review, we generate a comprehensive picture of HuR functionality to discuss the implications of considering HuR as pharmacological target and the detrimental or positive impact that can be expected upon its modulation. Firstly, we focus on the recent findings about the mechanistic role of HuR in the nucleus and in the regulation of long non coding RNAs; then we describe the animal models and the clinical association and significance in cancer; finally, we have reviewed the pharmacological tools that influence HuR’s post-transcriptional control and the efforts made to identify specific HuR inhibitors.
- 1 April 2014
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 349 (1) , 99-106
Loss of Protein Kinase Cδ/HuR Interaction Is Necessary to Doxorubicin Resistance in Breast Cancer Cell Lines
The protein kinase Cδ (PKCδ) interacts with and phosphorylates HuR, dictating its functionality. We show here that the genotoxic stimulus induced by doxorubicin triggers PKCδ interaction with HuR and leads to HuR phosphorylation on serines 221 and 318 and cytoplasmic translocation. This series of events is crucial to elicit the death pathway triggered by doxorubicin and is necessary to promote HuR function in post-transcriptional regulation of gene expression, because genetic ablation of PKCδ caused the inability of HuR to bind its target mRNAs, topoisomerase IIα (TOP2A) included. In in vitro select doxorubicin-resistant human breast cancer cell lines upregulating the multidrug resistance marker ABCG2, PKCδ, and HuR proteins were coordinately downregulated together with the doxorubicin target TOP2A protein whose mRNA was HuR-regulated. Therefore, we show here that PKCδ, HuR, and TOP2A constitute a network mediating doxorubicin efficacy in breast cancer cells. The importance of these molecular events in cancer therapy is suggested by their being profoundly suppressed in cells selected for doxorubicin resistance.
- 1 April 2014
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 349 (1) , 99-106
Loss of Protein Kinase Cδ/HuR Interaction Is Necessary to Doxorubicin Resistance in Breast Cancer Cell Lines
The protein kinase Cδ (PKCδ) interacts with and phosphorylates HuR, dictating its functionality. We show here that the genotoxic stimulus induced by doxorubicin triggers PKCδ interaction with HuR and leads to HuR phosphorylation on serines 221 and 318 and cytoplasmic translocation. This series of events is crucial to elicit the death pathway triggered by doxorubicin and is necessary to promote HuR function in post-transcriptional regulation of gene expression, because genetic ablation of PKCδ caused the inability of HuR to bind its target mRNAs, topoisomerase IIα (TOP2A) included. In in vitro select doxorubicin-resistant human breast cancer cell lines upregulating the multidrug resistance marker ABCG2, PKCδ, and HuR proteins were coordinately downregulated together with the doxorubicin target TOP2A protein whose mRNA was HuR-regulated. Therefore, we show here that PKCδ, HuR, and TOP2A constitute a network mediating doxorubicin efficacy in breast cancer cells. The importance of these molecular events in cancer therapy is suggested by their being profoundly suppressed in cells selected for doxorubicin resistance.
- 31 July 2012
- Published by Elsevier in European Journal of Cancer
- Vol. 48, S247
1024 HuR Expression Level and Posttranslational Modifications are Key Factors in Breast Cancer Cell Lines Doxorubicin Resistance
- 31 July 2012
- Published by Elsevier in European Journal of Cancer
- Vol. 48, S247
1024 HuR Expression Level and Posttranslational Modifications are Key Factors in Breast Cancer Cell Lines Doxorubicin Resistance